Stroke and AF.

Slides:



Advertisements
Similar presentations
Atrial fibrillation and subcutaneous monitoring : Will it change our daily practice ? Aymeric MENET Lille January 2016.
Advertisements

R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.
Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
Silent No More:.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.
Atrial Fibrillation and PCI
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
Updates in Anticoagulation: What Did We Learn From ESC 2017?
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
The ABCs of AF.
NOACs in Clinical Practice: Are They All the Same?
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Nat. Rev. Cardiol. doi: /nrcardio
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
How to Adjust Anticoagulant Dosing
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
The Essentials for Secondary Stroke Prevention
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Efficacy and Safety of Edoxaban in Patients With AF and HF
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
What Anticoagulant Registries Are Revealing
Watching for the Patient With AF: Latest Advances and Technologies
Daniel Frenkel et al. JACEP 2016;2:
VTE in Cancer.
Oral Anticoagulation in AF
Nat. Rev. Cardiol. doi: /nrcardio
Dos and Don’ts for High-Risk Elderly Patients With AF
Atrial Fibrillation.
Taking the "Cryptogenic" Out of Cryptogenic Stroke
NOACs in AF: Consequences of Underdosing and NonAdherence
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Identifying High-Risk AF Patients
Study Background and Rationale Updated October 24, 2018
Factor Xa Inhibitors in PAD
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Updates in Anticoagulation: Key Sessions at ESC 2017
Antithrombotics in Arterial Disease: Focus on Coronary Disease
Program Goals Background: Anticoagulation in Patients With VTE.
NOACs in AF: Consequences of Underdosing and NonAdherence
The ABCs of AF.
Taking the "Cryptogenic" Out of Cryptogenic Stroke
5 Good Minutes on Atrial Fibrillation-related Stroke
What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.
Nat. Rev. Cardiol. doi: /nrcardio
How to Adjust Anticoagulant Dosing
Antiarrhythmic Drugs in AF
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Erratum Canadian Journal of Cardiology
Reassessing Risk Stratification in CAD/PAD
Figure 8. Stroke prevention strategy in patients with AF
Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.
Extraordinary Cases in Stroke Prevention
What's New in NOACs in AF?.
Presentation transcript:

Stroke and AF

CV Outcomes in NOAC Trials

NOACs: 4-Trial Meta-Analysis

Silent AF The Clinical Relevance

Asymptomatic AF A Silent Epidemic

Different Monitoring Methods to Detect AF

ASSERT: Silent AF and the Risk of Stroke

Temporal Relation of SCAF With Stroke/SE

TRENDS Study

Management of Patients With AHREs

NOAH-AFNET 6 Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

NOAH-AFNET 6: Inclusion Criteria

Risk of TEs Based on the Presence of AF, Duration of AF, and CHADS2

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.